Our current influenza vaccines are strain-specific ... To a lesser extent, the virus can also use another protein called neuraminidase (NA). Then, once it attaches itself, the virus starts to ...

Two surface proteins, HA and NA, determine the antigenic properties of influenza virus strains. In 1958, a new strain of influenza A with different HA and NA was identified and antigenic shift was ...

Two surface glycoproteins, hemagglutinin (HA) and neuraminidase (NA), and the M2 ion-channel protein are embedded in the viral envelope, which is derived from the host's plasma membrane.

Designed to support the development of vaccines for the 2025–2026 northern hemisphere influenza season, the new offerings include high-quality recombinant HA, NA and NP proteins. These reagents are ...

For each protein, its corresponding RNA genomic segment is indicated, as well as its approximate molecular weight (in kDa). *Compounds identified with antiviral activity in experimental trials.

Designed to support the development of vaccines for the 2025-2026 northern hemisphere influenza season, the new offerings include high-quality recombinant HA, NA, and NP proteins. These reagents are ...

Subsequent work has described different versions of the virus surface proteins hemagglutinin (HA) and neuraminidase (NA). Different combinations of these give rise to the influenza A virus ...

Influenza vaccine ... a nuclear protein and the polymerase complex, which are both encoded by the viral genome. Variations in the HA and NA genes determine the subtype and strain.